Tag: Drug candidate

Browse exclusive Tags!

Alterity Therapeutics to Host Investor Webcast on Recent Clinical Progress and Efficacy Data of ATH434 in Neurodegenerative Diseases, Australia

Discover the latest clinical progress and efficacy data of ATH434 in neurodegenerative diseases with Alterity Therapeutics' CEO in an upcoming investor webcast. Register now for valuable insights!

UNITY Biotechnology Reports Positive Results for UBX1325 in Diabetic Macular Edema

UNITY Biotechnology reports positive results for UBX1325 in treating diabetic macular edema (DME), providing a potential solution for patients not benefiting from current therapies.

Preliminary Analysis: SN132D Shows Promising Safety Profile in Endometriosis Patients

Read the preliminary analysis of Spago Nanomedical's phase IIa study on SN132D, a potential MRI contrast agent for endometriosis patients.

Popular

UNITY Biotechnology Reports Positive Results for UBX1325 in Diabetic Macular Edema

UNITY Biotechnology reports positive results for UBX1325 in treating diabetic macular edema (DME), providing a potential solution for patients not benefiting from current therapies.

Alterity Therapeutics to Host Investor Webcast on Recent Clinical Progress and Efficacy Data of ATH434 in Neurodegenerative Diseases, Australia

Discover the latest clinical progress and efficacy data of ATH434 in neurodegenerative diseases with Alterity Therapeutics' CEO in an upcoming investor webcast. Register now for valuable insights!

Subscribe

spot_imgspot_img